Florida State University
College of Law
Advocacy Center, Room A227A
J.D., Vanderbilt Law School, 2015
M.D., Tufts University School of Medicine, 2011
B.A., Amherst College, 2000
Dr. Mason Marks is The Florida Bar health law section professor at the Florida State University College of Law. At Harvard Law School, he is the senior fellow and project lead of the Project on Psychedelics Law and Regulation (POPLAR) at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics. He is also an affiliated fellow at the Information Society Project (ISP) at Yale Law School. Marks was previously a fellow in residence at the Edmond J. Safra Center for Ethics at Harvard University, a research scholar at the Information Law Institute at NYU Law School, and a visiting fellow at Yale Law School’s ISP.
His academic research focuses on drug policy, data protection, and FDA regulation. He is particularly interested in controlled substance regulation and the application of artificial intelligence to medical decision making. Marks’s academic writing has been published or is forthcoming in the Duke Law Journal, Harvard Law Review Forum, Boston University Law Review, UC Irvine Law Review, UC Davis Law Review, Administrative Law Review, Yale Journal of Law and Technology, Nature Medicine, Neuropharmacology, the NYU Journal of Legislation and Public Policy, and books by Cambridge University Press.
In addition to legal scholarship, Marks writes about law and technology for publications such as the Washington Post, the Los Angeles Times, the Guardian, the Seattle Times, Wired, Slate, Vice News, Gizmodo, STAT News, and the Houston Chronicle. His legal commentary has been featured by the New York Times, the Wall Street Journal, the Washington Post, ABC News, Fox News, Bloomberg News, the Economist, Radio Boston, German Public Radio, and NPR's All Things Considered.
Marks teaches Constitutional Law, Administrative Law, Drug Law, and seminars on technology and the First Amendment. An expert on the fast-emerging psychedelics industry, he advises local, state, and federal lawmakers and regulators on the rapidly evolving regulatory landscape regarding controlled substances. He has presented his research at the Food and Drug Administration, the National Institutes of Health, the Department of Health and Human Services, and the National Academies of Sciences, Engineering, and Medicine.
Marks writes about drug policy for his newsletter Psychedelic Week. His book on psychedelic law and politics will be published by Yale University Press.
Select Recent and Forthcoming Publications
Psychedelic Law and Politics (Yale University Press) (forthcoming 2024)
Microdosing Under State and Federal Law, with I. Glenn Cohen, __ Boston University Law Review __ (forthcoming 2023)
The Varieties of Psychedelic Law, 226 Neuropharmacology 1 (2023)
Automating FDA Regulation, 71 Duke L. J. 1207 (2022)
Patents on Psychedelics: The Next Legal Battlefront of Drug Development, 135 Harvard L. Rev. F. 212 (2022)
Biosupremacy: Big Data, Antitrust, and Monopolistic Power Over Human Behavior, 55 U.C. Davis L. Rev. 995 (2022)
Emergent Medical Data: Health Information Inferred by Artificial Intelligence, 11 U.C. Irvine L. Rev. 995 (2021)
Psychedelic Therapies: A Roadmap for Wider Acceptance and Utilization, with I. Glenn Cohen, 27 Nature Medicine 1669 (2021)
Controlled Substance Regulation for the COVID-19 Mental Health Crisis, 72 Admin. L. Rev. 649 (2020)
Artificial Intelligence Based Suicide Prediction, 21 Yale J. L. & Tech. 98 (2019)